| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Venetoclax |
| Brand | Venclyxto® |
| Indication | For the treatment of chronic lymphocytic leukaemia (CLL) |
| Assessment Process | |
| Rapid review commissioned | 03/01/2017 |
| Rapid review completed | 08/02/2017 |
| Rapid review outcome | Full HTA not recommended until further evidence available |
Rapid Review
| Commenced | Completed | Outcome |
| 08/05/2018 | 21/06/2018 | Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies. |
The HSE has approved reimbursement following confidential price negotiations – December 2018.
